Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial

B. Rossetti, R. Gagliardini, G. Meini, G. Sterrantino, V. Colangeli, M.C. Re, A. Latini, M. Colafigli, F. Vignale, S. Rusconi, V. Micheli, A.D. Biagio, G. Orofino, V. Ghisetti, A. Fantauzzi, V. Vullo, P. Grima, D. Francisci, C. Mastroianni, A. AntinoriM. Trezzi, L. Lisi, P. Navarra, B. Canovari, A. D’Arminio Monforte, S. Lamonica, A. D’Avino, M. Zazzi, S.D. Giambenedetto, A. De Luca

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article numbere0187393
Number of pages18
JournalPLoS One
Issue number11
Publication statusPublished - Nov 21 2017

Cite this